Mr. George Reznik reports

LIGHT AI ANNOUNCES EXPANSION OF ITS WELLNESS PLATFORM

Light AI Inc.'s innovative wellness platform, anticipated to launch in Q3 of 2025, is expanding its capabilities to help users rule out COVID-19 and conjunctivitis (pink eye), in addition to strep A.

The wellness platform is a direct-to-consumer product designed to support the quick detection and management of these conditions and will serve as a cornerstone in Light AI's expanding suite of health care tools aimed at supporting millions of families and individuals worldwide.

These additional medical conditions expand Light AI's addressable market and are anticipated to enhance revenue and opportunities for licensing and partnership. This illustrates the company's progress toward its ultimate goal of being a one-stop application to enhance health and wellness.

"Timely diagnosis is known to drive better health outcomes, yet nearly 50 per cent of the global population lacks access to basic diagnostics, exposing a massive gap in care and a high-growth market ripe for innovation," said Peter Whitehead, chief executive officer of Light AI. "For these reasons, we are thrilled to introduce our comprehensive wellness platform, which will empower families and individuals to manage common yet impactful health issues more effectively."

Strep A

Group A strep, a common yet potentially serious infection, can cause significant health complications if not managed properly. Light AI's app will leverage advanced machine learning (ML) algorithms to provide accurate and timely diagnosis, empowering families to manage this condition more effectively. Light AI's management team is confident that this application will be a powerful attractor, encouraging the adoption of other critical health care solutions.

COVID-19

The persistent presence of COVID-19 continues to strain health care resources, particularly in settings housing high-risk individuals such as long-term care facilities. These establishments face continuing challenges related to infection control, staffing, and adequate vaccination coverage among residents and staff.

Conjunctivitis

Light AI's machine learning team has successfully developed an algorithm that can rapidly advise if affected individuals can rule out conjunctivitis with an impressive 99-per-cent accuracy rate. Conjunctivitis is a highly infectious condition affecting approximately six million people annually in the United States alone and can lead to severe complications such as cellulitis, orbital cellulitis, keratitis, corneal ulcers and scarring, potentially increasing the risk of permanent vision impairment if left untreated.

Light AI's dedicated team is currently working to advance diagnostics on health care issues and will provide updates as new algorithms are refined. This expanded ecosystem will not only provide economies of scale to support market demand but will also generate valuable data to enhance predictive algorithms for future health care solutions.

About Light AI Inc.

Light AI is a technology company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform that represents the next generation of patient management: It applies AI algorithms to smart phone images -- starting with images of strep A -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind; its hardware platform is the 4.5 billion smart phones that exist in the world today. Light AI is at the forefront of developing innovative diagnostic solutions aimed at improving health care delivery worldwide. Its cutting-edge AI-powered technology offers rapid, accurate and cost-effective diagnostic tools designed to address critical health care challenges.

In pre-FDA (U.S. Food and Drug Administration) validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A streptococcus (GAS). The algorithm achieved a 96.57-per-cent accuracy rate and attained a negative predictive value of 100 per cent, indicating its high reliability in confirming the absence of streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease (RHD), which imposes a global economic burden exceeding $1-trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

We seek Safe Harbor.